within Pharmacolibrary.Drugs.ATC.L;

model L01XB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 39 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.00047,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Procarbazine is an oral alkylating agent used primarily for the treatment of Hodgkin's lymphoma and certain brain tumors such as gliomas. It is often administered as part of the chemotherapy regimen MOPP (mechlorethamine, vincristine, procarbazine, and prednisone). Its use in modern clinical practice has decreased due to the development of newer agents with improved safety profiles.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with cancer (primarily Hodgkin's lymphoma and brain tumors) after oral administration.</p><h4>References</h4><ol><li><p>Ewesuedo, RB, &amp; Dolan, ME (2000). Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. <i>Cancer chemotherapy and pharmacology</i> 46(2) 150–155. DOI:<a href=&quot;https://doi.org/10.1007/s002800000121&quot;>10.1007/s002800000121</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10972485/&quot;>https://pubmed.ncbi.nlm.nih.gov/10972485</a></p></li><li><p>Grossman, SA, et al., &amp; Supko, JG (2006). The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 12(17) 5174–5181. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-06-0932&quot;>10.1158/1078-0432.CCR-06-0932</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16951236/&quot;>https://pubmed.ncbi.nlm.nih.gov/16951236</a></p></li><li><p>Patel, PM, et al., &amp; McElwain, TJ (1993). Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. <i>Hematological oncology</i> 11(2) 89–96. DOI:<a href=&quot;https://doi.org/10.1002/hon.2900110206&quot;>10.1002/hon.2900110206</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8406379/&quot;>https://pubmed.ncbi.nlm.nih.gov/8406379</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XB01;
